Introduction
C24H44O6 is a molecular formula that identifies a class of neutral triacylglycerols (TAGs) in which three identical fatty acid chains of seven carbon atoms each are esterified to a glycerol backbone. The compound is commonly referred to as triheptanoin, a triglyceride of heptanoic acid. Triheptanoin has attracted attention in the fields of organic chemistry, nutrition science, and medical therapeutics, particularly for its role in the treatment of certain inherited metabolic disorders. The compound is of interest due to its distinctive biochemical behavior, which contrasts with more familiar saturated TAGs such as triolein or tripalmitin.
Triheptanoin is distinguished from other short- and medium-chain triglycerides by its capacity to provide anaplerotic substrates for the tricarboxylic acid (TCA) cycle, a property that underlies its therapeutic application. In metabolic pathways, the beta‑oxidation of seven‑carbon fatty acids yields propionyl‑CoA, a three‑carbon unit that can replenish TCA cycle intermediates. This anaplerotic potential is less pronounced in triglycerides composed of longer chains, which produce only acetyl‑CoA upon oxidation. Consequently, triheptanoin occupies a unique niche among fatty acids that balance energy provision with metabolic support.
From a synthetic standpoint, triheptanoin can be obtained via enzymatic or chemical esterification of glycerol with heptanoic acid under controlled conditions. Industrial production typically employs transesterification of crude oil sources or direct esterification in the presence of acid catalysts. The purification process yields a colorless, odorless liquid that exhibits a melting point near −8 °C, allowing it to remain liquid at ambient temperature. Its physical properties, including density and viscosity, are intermediate between short‑chain oils such as medium‑chain triglycerides (MCTs) and longer‑chain TAGs like coconut oil.
The present article presents an overview of the chemical nature, properties, synthesis, natural occurrence, and applications of C24H44O6, with a focus on its role as triheptanoin. The discussion aims to provide a comprehensive understanding suitable for readers with a background in chemistry, biochemistry, or pharmaceutical sciences.
Chemical Composition and Structure
Formula and Isomerism
The empirical formula C24H44O6 indicates that the molecule comprises 24 carbon atoms, 44 hydrogen atoms, and 6 oxygen atoms. In a triacylglycerol, the molecular architecture consists of a glycerol backbone (C3H8O3) to which three fatty acid chains are attached via ester linkages. Each ester bond introduces one oxygen atom, contributing three of the six oxygens in the formula. The remaining three oxygen atoms are present as hydroxyl groups in the glycerol core before esterification. The distribution of hydrogens reflects the fully saturated nature of the fatty acid chains; all carbon–hydrogen bonds are single, and no double bonds or aromatic rings are present.
Isomeric considerations for C24H44O6 are limited because the fatty acid chains are identical, and the glycerol backbone does not possess stereocenters that would give rise to enantiomers in this case. However, the position of the fatty acid chains (sn‑1, sn‑2, sn‑3) on glycerol can theoretically vary. In natural triglycerides, the sn‑2 position is often preferentially occupied, but synthetic preparations of triheptanoin generally yield a mixture of positional isomers with negligible impact on overall physicochemical behavior. Because all chains are 7 carbons long and saturated, the molecule is non‑conjugated and displays a single structural motif that is preserved across isomeric forms.
Structural Representation
At the molecular level, triheptanoin can be represented as 1,3‑bis(heptanoyl)‑2‑(heptanoyloxy)‑glycerol. The glycerol core is a three‑carbon chain with hydroxyl groups at each carbon. Two of these hydroxyl groups are replaced by esterified heptanoic acid moieties, yielding an acylated chain with the general formula –O–C(=O)–(CH2)5–CH3. The third hydroxyl group remains free, but in the context of triacylglycerol synthesis it is also esterified, completing the triester structure. The overall molecular weight of triheptanoin is 452.66 g mol⁻¹, calculated by summing the atomic weights of its constituent atoms.
Computational modeling and spectroscopic techniques (e.g., nuclear magnetic resonance and mass spectrometry) confirm the absence of unsaturation and the presence of three identical acyl chains. In solution, the molecule adopts a flexible conformation that facilitates interaction with lipid membranes and aqueous environments. The distribution of hydrophobic and hydrophilic regions allows triheptanoin to form micelles and emulsions, properties that are exploited in pharmaceutical formulations and nutritional applications.
Physical and Chemical Properties
- Molecular weight: 452.66 g mol⁻¹
- Melting point: approximately –8 °C (liquid at room temperature)
- Boiling point: estimated 315 °C (decomposition prior to boiling)
- Density: 0.92 g cm⁻³ at 20 °C
- Viscosity: 5–6 cP at 25 °C (low to moderate)
- Solubility: insoluble in water; soluble in organic solvents such as hexane, diethyl ether, and ethanol
- Flammability: highly flammable; ignition temperature ~140 °C
- Reactivity: stable under neutral pH; susceptible to oxidation in the presence of metal ions or peroxides
The melting point of triheptanoin places it in the category of low‑melting, liquid oils that are suitable for oral delivery. Its low density relative to water reflects its high fatty acid content. Viscosity measurements indicate that triheptanoin behaves as a Newtonian fluid at physiological temperatures, simplifying its incorporation into lipid emulsions and pharmaceutical preparations.
Triheptanoin is characterized by a relatively low propensity for autooxidation compared to longer‑chain triglycerides, owing to the saturated nature of the chains and the lack of double bonds. Nonetheless, storage under elevated temperatures or in the presence of light can accelerate oxidation, producing peroxides that may pose health risks. Antioxidants such as tocopherol are sometimes added to commercial preparations to mitigate oxidation and extend shelf life.
In aqueous environments, triheptanoin displays limited solubility, but the presence of surfactants or emulsifiers can facilitate its dispersion. The resulting emulsions are stable over a wide pH range and exhibit minimal phase separation, attributes that are advantageous for both pharmaceutical and nutritional formulations.
Synthesis and Production
- Direct esterification: Glycerol reacts with heptanoic acid in the presence of a strong acid catalyst (e.g., sulfuric acid or p-toluenesulfonic acid) under reflux. The reaction proceeds through protonation of the carboxyl group, facilitating nucleophilic attack by the glycerol hydroxyl groups. Excess heptanoic acid drives the equilibrium toward completion. The reaction mixture is then neutralized and the product purified by distillation or chromatography.
- Transesterification: A pre‑existing triglyceride (e.g., triolein) can be transesterified with heptanoic acid using a base catalyst such as sodium methoxide. This process exchanges the fatty acid chains of the triglyceride, replacing longer chains with heptanoic acid. Transesterification is typically performed under controlled temperature and pressure to avoid side reactions and ensure high yield.
- Enzymatic synthesis: Lipase enzymes, often immobilized on solid supports, catalyze esterification or transesterification under mild conditions. Enzymatic routes offer high selectivity and avoid the need for harsh acids or bases, making them attractive for pharmaceutical-grade production.
Industrial production of triheptanoin generally employs the direct esterification method due to its simplicity and scalability. Glycerol is sourced as a by‑product of biodiesel manufacturing, while heptanoic acid is either extracted from natural sources (e.g., certain plant oils) or synthesized via catalytic hydrogenation of shorter‑chain fatty acids. Process parameters such as temperature, reaction time, and catalyst concentration are optimized to maximize yield and minimize by‑product formation.
Purification steps typically involve removal of residual acids and catalysts, followed by distillation under reduced pressure to eliminate volatile impurities. The final product is often formulated as a clear, colorless oil with a mild odor. Quality control tests assess purity, residual catalyst levels, peroxide values, and fatty acid composition, ensuring compliance with pharmacopeial standards.
Recycling of catalysts and waste streams is a key consideration in large‑scale operations. Acidic catalysts can be regenerated by neutralization and re‑acidification, while base catalysts are recovered via ion exchange techniques. Glycerol by‑products may be recycled to reduce raw material costs and improve overall process sustainability.
Occurrence
- Natural sources: Triheptanoin is not typically found in significant concentrations in natural oils. However, short‑chain triglycerides are present in certain animal fats and some plant extracts. The presence of triheptanoin itself has been reported in trace amounts in the lipid fraction of some sea‑weed species, though concentrations are usually below detectable limits with standard analytical methods.
- Industrial synthesis: Commercially, triheptanoin is produced through chemical synthesis rather than extraction. The controlled nature of synthesis allows for consistent production of the desired fatty acid chain length.
- Pharmaceutical formulations: In therapeutic contexts, triheptanoin is incorporated into lipid emulsions used for parenteral nutrition or oral supplementation. The formulations often include co‑administration of other fatty acids to balance caloric density and nutrient composition.
The scarcity of triheptanoin in natural sources underscores its primary role as a synthetic or semi‑synthetic product. In contrast, longer‑chain triglycerides dominate natural fats and oils, leading to differences in metabolic processing and clinical utility. The targeted synthesis of triheptanoin allows researchers to exploit its unique metabolic pathways, particularly the anaplerotic contribution of propionyl‑CoA.
Applications
Medical Uses
Triheptanoin has gained recognition as a therapeutic agent for the management of certain inherited metabolic disorders, most notably fatty acid oxidation defects (FAODs) and inherited hypoglycemia. Its administration replenishes TCA cycle intermediates via the conversion of propionyl‑CoA to succinyl‑CoA, thereby supporting energy production in tissues with impaired oxidative capacity. Clinical trials have demonstrated that triheptanoin can reduce the frequency of hypoglycemic episodes and improve exercise tolerance in patients with FAODs.
In the context of metabolic encephalopathies, triheptanoin has been evaluated for its potential to ameliorate cognitive deficits by providing an alternative anaplerotic substrate. Studies indicate that the compound can cross the blood–brain barrier and participate in neuronal metabolic cycles, offering a novel avenue for the treatment of refractory seizures associated with metabolic disorders.
Beyond monogenic disorders, triheptanoin is investigated as an adjunct therapy in oncology. Tumor cells often exhibit altered metabolic requirements, and the anaplerotic pathway mediated by triheptanoin may provide a means to modulate tumor metabolism, although definitive clinical evidence remains limited. Preliminary pre‑clinical studies in murine tumor models suggest that triheptanoin can interfere with lactate production and reduce tumor proliferation.
Parenteral nutrition regimens for neonatal intensive care units sometimes incorporate triheptanoin to deliver high‑quality calories to preterm infants with metabolic vulnerabilities. The lipid emulsions are formulated to maintain isotonicity, prevent lipid accumulation, and provide essential fatty acids while delivering the anaplerotic benefits of the short‑chain triglyceride.
Nutritional and Supplementary Uses
Triheptanoin serves as a dietary supplement aimed at individuals with dietary restrictions or specific caloric needs. Its lower melting point facilitates rapid absorption in the gastrointestinal tract, providing a fast‑acting source of energy. The oil is often marketed under brand names that emphasize its role in supporting athletic performance, promoting recovery, and maintaining metabolic health.
In weight‑management programs, triheptanoin is occasionally combined with omega‑3 and omega‑6 fatty acids to create balanced lipid blends. The short chain length ensures rapid oxidation, offering a more controlled caloric release compared to longer‑chain fats.
Pharmaceutical Formulations
Formulating triheptanoin into lipid emulsions requires careful selection of emulsifiers, such as polysorbate 80 or lecithin, to achieve stable micro‑emulsions. The emulsions are designed for parenteral administration, enabling direct entry into systemic circulation. The oil is also formulated in enteric‑coated capsules for oral use, ensuring protection from gastric acid and release at target sites.
Pharmaceutical preparations of triheptanoin adhere to stringent quality standards. The drug product is typically supplied in sterile vials with a 5 % (w/v) lipid concentration, accompanied by an appropriate excipient blend. Storage conditions emphasize refrigeration and protection from light to prevent oxidation.
Regulatory approval for triheptanoin involves demonstrating safety, efficacy, and quality through the phases of drug development. The compound has been approved by regulatory authorities in select regions for the treatment of FAODs, and further approvals are anticipated as additional clinical data accumulate.
Pharmacokinetics
- Absorption: Rapid uptake from the gastrointestinal tract following oral dosing; intravenous administration bypasses absorption barriers.
- Distribution: Triheptanoin distributes preferentially to skeletal muscle and cardiac tissue, with measurable levels in the central nervous system after crossing the blood–brain barrier.
- Metabolism: β‑oxidation of heptanoyl chains yields acetyl‑CoA; propionyl‑CoA production follows hydrolysis of heptanoyl chains to propionyl‑CoA and subsequent carboxylation to succinyl‑CoA.
- Elimination: The primary elimination route is via hepatic metabolism; excretion occurs through bile excretion of conjugated metabolites or via renal excretion of low‑molecular‑weight intermediates.
Pharmacokinetic studies indicate that triheptanoin achieves peak plasma concentrations within 30–60 minutes of oral dosing. The short residence time in plasma reflects rapid uptake by peripheral tissues. The concentration–time profile is bell‑shaped, with rapid clearance from circulation as metabolism proceeds. This profile facilitates dosing regimens that maintain therapeutic levels while minimizing potential toxicity.
Metabolic studies in animal models reveal that triheptanoin is absorbed into the portal circulation and shuttled to the liver, where the heptanoyl chains undergo β‑oxidation. The generation of propionyl‑CoA is then funneled into the anaplerotic pathway, producing succinyl‑CoA and replenishing the TCA cycle. The net effect is an increase in ATP production and a reduction in metabolic stress markers such as lactate and ketone bodies.
In patients with FAODs, the addition of triheptanoin has been shown to improve metabolic flexibility, allowing tissues to switch between carbohydrate and fatty acid oxidation more effectively. The therapeutic window for triheptanoin is broad, with effective doses ranging from 0.5 to 5 g kg⁻¹ per day, depending on patient age, weight, and disease severity.
Safety and Toxicology
- Acute toxicity: LD₅₀ in rodents > 5 g kg⁻¹ (oral), indicating low acute toxicity
- Chronic toxicity: No significant organ damage observed at therapeutic doses; hepatic function remains stable with proper antioxidant supplementation
- Carcinogenicity: No evidence of carcinogenic activity in long‑term studies; peroxidation products are low under controlled conditions
- Genotoxicity: Negative in standard Ames and micronucleus tests, indicating no mutagenic potential
- Allergenicity: Minimal allergenic potential due to absence of protein contaminants; however, patients with lipid hypersensitivity may exhibit adverse reactions.
The safety profile of triheptanoin supports its use in pediatric and adult populations with metabolic disorders. Regulatory agencies require that any pharmaceutical preparation include a detailed risk assessment and patient monitoring plan, particularly for patients with pre‑existing hepatic dysfunction.
Potential adverse effects include mild gastrointestinal discomfort, transient flushing, and rare allergic reactions. Monitoring for signs of oxidative stress and lipid peroxidation is essential, especially in patients receiving high doses or long‑term therapy.
Because triheptanoin is a lipid, it is classified as a drug requiring parenteral safety assessment for injection. Sterility, pyrogenicity, and viscosity are evaluated according to the guidelines set by the United States Pharmacopeia and the European Pharmacopoeia.
Conclusion
Triheptanoin, identified by its chemical formula C24H44O6, represents a distinctive saturated triacylglycerol composed of three identical 7‑carbon fatty acid chains. Its physicochemical properties, such as low melting point and high stability, make it suitable for pharmaceutical and nutritional applications. The primary utility of triheptanoin lies in its medical role as an anaplerotic agent for the treatment of inherited metabolic disorders. Synthesis via direct esterification, transesterification, or enzymatic routes yields pharmaceutical‑grade oil that is incorporated into lipid emulsions and oral supplements.
In the broader landscape of lipid science, triheptanoin stands out for its unique metabolic contributions, particularly the provision of propionyl‑CoA and subsequent TCA cycle anaplerosis. Continued research into its therapeutic efficacy, formulation optimization, and process sustainability holds promise for expanding its clinical impact and ensuring its availability as a safe, effective therapeutic lipid.
No comments yet. Be the first to comment!